Riskpilot← Back to searchSign inGet full accessCONTERA PHARMA A/S
A/SActiveCVR 33062214Venlighedsvej 4Research and experimental development on natural sciences and engineering · NACE 7210Est. 201019 employeeswww.conterapharma.com
Revenue 2025
DKK 20,6M
-138% vs 2024
EBITDA margin
-20.2%
+94% vs 2024
Equity ratio
81.5%
Financial strength
Net profit 2025
DKK -4,8M
+93% vs 2024
| Revenue | DKK 20,6M | -138% |
| EBITDA | DKK -4,2M | +94% |
| Net profit | DKK -4,8M | +93% |
| Total assets | DKK 97,6M | +53% |
| Equity | DKK 79,5M | +46% |
| Employees | 19 | — |
Legal name
CONTERA PHARMA A/S
CVR number
33062214
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9. juli 2010
Share capital
DKK 2.708.158
Employees
19 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsesformanden i forening med selskabets administrerende direktør.
Company purpose
Selskabets formål er at udvikle nye lægemidler og dermed beslægtet virksomhed.
Address
Venlighedsvej 4
Phone
+4531186611
Email
ts@conterapharma.com
Website
www.conterapharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -3.690 | -3.423 | -126 | 445 | 3.108 | 1.419 | 1.519 | -1.250 | -9.725 | -24.154 | -44.832 | -58.994 | -54.084 | 20.632 |
| Staff expenses | -1.690 | -1.934 | -2.987 | -1.490 | -1.751 | -1.721 | -1.288 | -928 | -3.720 | -12.112 | -13.226 | -17.994 | -19.859 | -24.803 |
| EBITDA | -5.380 | -5.357 | -3.113 | -1.044 | 1.357 | -303 | 231 | -2.178 | -13.445 | -36.266 | -58.058 | -76.988 | -73.985 | -4.171 |
| Depreciation & amort. | -16 | -16 | -16 | -9 | -0 | -0 | -0 | -0 | -52 | -126 | -4.026 | -1.272 | -1.642 | -1.813 |
| EBIT | -5.396 | -5.373 | -3.129 | -1.054 | 1.357 | -303 | 231 | -2.178 | -13.496 | -36.392 | -62.084 | -78.260 | -75.626 | -5.984 |
| Net financials | 83 | -42 | -220 | -27 | -8 | 6 | -5 | -8 | -339 | -189 | -285 | 1.439 | 913 | -79 |
| Profit before tax | -5.313 | -5.415 | -3.348 | -1.081 | 1.350 | -297 | 226 | -2.186 | -13.835 | -36.581 | -62.368 | -76.820 | -74.714 | -6.063 |
| Tax | -1.068 | -688 | -111 | 2 | 483 | 122 | 1.193 | -183 | -1.576 | -5.062 | -5.500 | -5.500 | -5.500 | -1.279 |
| Net profit | -4.245 | -4.726 | -3.237 | -1.083 | 866 | -419 | -968 | -2.003 | -12.259 | -31.519 | -56.868 | -71.320 | -69.214 | -4.784 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 6.750 | 4.111 | 1.879 | 852 | 1.648 | 1.423 | 3.639 | 18.225 | 201.326 | 167.213 | 115.743 | 92.369 | 63.610 | 97.551 |
| Equity | 6.402 | 1.676 | 1.684 | 601 | 1.467 | 1.048 | 3.203 | 17.800 | 194.961 | 163.442 | 106.574 | 86.298 | 54.388 | 79.472 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 349 | 2.436 | 195 | 252 | 181 | 375 | 436 | 425 | 6.365 | 3.771 | 9.169 | 6.071 | 9.222 | 18.079 |
| Total debt | 349 | 2.436 | 195 | 252 | 181 | 375 | 436 | 425 | 6.365 | 3.771 | 9.169 | 6.071 | 9.222 | 18.079 |
EBITDA margin
-20.2%
This company
15.8%
Market median
-228% vs market
20122025
Equity ratio
81.5%
This company
38.2%
Market median
+113% vs market
20122025
Return on equity
-6.0%
This company
18.4%
Market median
-133% vs market
20122025
Net profit margin
-23.2%
This company
8.1%
Market median
-386% vs market
20122025
Asset turnover
0.21×
This company
1.12×
Market median
-81% vs market
20122025
Debt / equity
0.23×
This company
0.62×
Market median
+63% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MS Management | Management | 2010 | — | — |
TN Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
JB Chief Executive Officer | Chief Executive Officer | 2010 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2011 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2012 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2011 | — | — | |
| Board of Directors | 2014 | — | — | |
| Board of Directors | 2012 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2013 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2026 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2013 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2014 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 90.0% | 90.0% | 2024 | |
| Individual | 25.0% | 25.0% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CONTERA PHARMA A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mikael Søndergaard Thomsen | Management | 0 companies |
| Thomas Nikolaj Sager | Chief Executive Officer | 0 companies |
| John Bondo Hansen | Chief Executive Officer | 0 companies |
| Jee Hun Kim | Board of Directors | 0 companies |
| Bobby G Soni | Board of Directors | 0 companies |
| Eun Ju Kim | Board of Directors | 0 companies |
| Gunnar Magnus Severus Modee Persson | Board of Directors | 0 companies |
| Jung Yoon Um | Board of Directors | 0 companies |
| Soo Yeon Park | Board of Directors | 0 companies |
| Frank Knudsen | Board of Directors | 0 companies |
| Sang Hoon Kim | Board of Directors | 0 companies |
| Carsten Schou | Board of Directors | 0 companies |
| Mahmoud Mahmoudian | Board of Directors | 0 companies |
| Joseph Donald deBethizy | Chairman | 0 companies |
| Paul Ejnar Gremaud Kristjansen | Board of Directors | 0 companies |
| Sun Ho Kim | Board of Directors | 0 companies |
| Mi Chung Ahn | Chairman | 0 companies |
| WooHyun Lee | Chairman | 0 companies |
| Else Sissel Vorstrup | Board of Directors | 0 companies |
| Sung Joon Kim | Board of Directors | 0 companies |
| Jae Young Lee | Board of Directors | 0 companies |
| Hee Won Yoo | Chairman | 0 companies |